2025
Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma.
Amer A, Ansari S, Krayyem A, Kundu S, Khose S, Pokhylevych H, Calle S, Patel C, Yang Z, Liu H, Johnson J. Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma. Journal Of Computer Assisted Tomography 2025 PMID: 39876523, DOI: 10.1097/rct.0000000000001716.Peer-Reviewed Original ResearchHigh-grade gliomasBlood-brain barrierDCE-MRIPeak contrast enhancementQuantify BBB permeabilityTreatment-related changesFollow-up subjectsKtrans mapsTrue progressionTumor progressionClinical dataConventional MRIPseudoprogressionBBB permeabilityCombined pathologyKtransContrast enhancementT1 enhancementStandard processing methodologyStatistically significant resultsClinical data setsPathologyPatientsGliomaSSS techniquePhase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas
Sahebjam S, Raval R, Forsyth P, Enderling H, Tran N, Arrington J, Macaulay R, Perlow H, Palmer J, Ghose J, Rajappa P, Giglio P, Li Z, Etame A, Mokhtari S, Cruz-Chamorro R, Bhandari M, Thapa R, Robinson T, Chen D, Yu H. Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas. Neuro-Oncology Advances 2025, 7: vdaf033. PMID: 40134851, PMCID: PMC11934552, DOI: 10.1093/noajnl/vdaf033.Peer-Reviewed Original ResearchTreatment-related adverse eventsStereotactic re-irradiationRecurrent high-grade gliomaHigh-grade gliomasRe-irradiationPD-1PD-1 blockadeProgression-free survivalPhase I studySecondary end pointsPhase 1 trialRecurrent HGGCheckpoint immunotherapyOverall survivalRecurrent glioblastomaAnaplastic astrocytomaBevacizumabNivolumabIpilimumabGrade 3Adverse eventsClinical investigationImmune responseEnd pointsPatients
2024
First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Chandana S, Choudhury N, Dowlati A, Chiang A, Garmezy B, Kim J, Byers L, Ahn M, Kim T, Kim Y, Han J, Bar J, Zha J, Henner W, Robinson R, KOHLHAPP F, Hingorani P, Papadopoulos K. First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2024, 42: 3001-3001. DOI: 10.1200/jco.2024.42.16_suppl.3001.Peer-Reviewed Original ResearchSmall cell lung cancerAntibody-drug conjugatesDose escalationNeuroendocrine neoplasmsCentral nervous systemRelapsed/refractory small cell lung cancerApproximate dose-proportional increasesHigh-grade CNS tumorsRecommended phase 2 doseModels of small cell lung cancerHigh-grade neuroendocrine neoplasmsFirst-in-human studyCentral nervous system tumorsClinical benefit rateDose-expansion studyMedian prior linesPhase 2 doseDose-limiting toxicityMaximum tolerated doseDose-proportional increaseCell lung cancerHigh-grade gliomasElimination half-lifeBayesian optimal interval designData cutoffTumors Affect the Metabolic Connectivity of the Human Brain Measured by 18F-FDG PET
Pasquini L, Jenabi M, Graham M, Peck K, Schöder H, Holodny A, Krebs S. Tumors Affect the Metabolic Connectivity of the Human Brain Measured by 18F-FDG PET. Clinical Nuclear Medicine 2024, 49: 822-829. PMID: 38693648, PMCID: PMC11300165, DOI: 10.1097/rlu.0000000000005227.Peer-Reviewed Original ResearchConceptsHealthy controlsTemporal tumorF-FDGFrontal tumorF-FDG PET/MRIKarnofsky performance scoreF-FDG PETHigh-grade gliomasLow-grade gliomasLow KPSRadiation necrosisActive tumorMetabolic brain networkMetabolic connectivityHigher KPSBrain metabolic connectivityHemispheric tumorsLow-gradeSignificant hemispheric differencesSynaptic activityTumorPatientsBetweenness centralityLeft hemisphere tumorsGlucose metabolismAdditive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas
Yadav D, Upadhyay R, Kumar V, Chen M, Johnson J, Langshaw H, Curl B, Farhat M, Talpur W, Beckham T, Yeboa D, Swanson T, Ghia A, Li J, Chung C. Additive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas. Practical Radiation Oncology 2024, 14: e449-e457. PMID: 38685448, DOI: 10.1016/j.prro.2024.04.009.Peer-Reviewed Original ResearchPseudo-progressionResponse assessmentInterobserver agreementImprove response assessmentPost-operative MRIFollow-up MRIFollow-up imagingEvaluate treatment responseHigh-grade gliomasIndependent blinded reviewIdentification of patientsClinical trial enrollmentWeeks of RTPartial response(PRStable disease(SDRT planningSalvage treatmentTumor responseEarly time pointsMedian intervalImprove patient outcomesTrue progressionProspective studyTreatment responseTumor progressionONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
Arrillaga-Romany I, Gardner S, Odia Y, Aguilera D, Allen J, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit K, Graber J, Haggiagi A, Harrison R, Kheradpour A, Kilburn L, Kurz S, Lu G, MacDonald T, Mehta M, Melemed A, Nghiemphu P, Ramage S, Shonka N, Sumrall A, Tarapore R, Taylor L, Umemura Y, Wen P. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal Of Clinical Oncology 2024, 42: 1542-1552. PMID: 38335473, PMCID: PMC11095894, DOI: 10.1200/jco.23.01134.Peer-Reviewed Original ResearchConceptsH3 K27M-mutant diffuse midline gliomaDiffuse midline gliomaDuration of responseTime to responseHigh-grade gliomasLow-grade gliomasMidline gliomaMedian duration of responseMedian time to responseTreatment-emergent adverse eventsEnd pointsBlinded independent central reviewCorticosteroid dose reductionIndependent central reviewSecondary end pointsClinically meaningful efficacyRadiographic end pointsSpinal tumorsDose reductionDismal prognosisCentral reviewPerformance scoresCorticosteroid responseResponse assessmentAdverse events
2023
CTNI-23. SINGLE CELL TRANSCRIPTOMICS, PHARMACOKINETICS, AND PHARMACODYNAMICS OF COMBINED CDK4/6 AND MTOR INHIBITION IN A PHASE 0 TRIAL OF RECURRENT HIGH-GRADE GLIOMA
Johnson K, Tien A, Jiang J, McNamara J, Chang Y, Montgomery C, DeSantis A, Elena L, Fujita Y, Kim S, Tovmasyan A, Li J, Mehta S, Verhaak R, Sanai N. CTNI-23. SINGLE CELL TRANSCRIPTOMICS, PHARMACOKINETICS, AND PHARMACODYNAMICS OF COMBINED CDK4/6 AND MTOR INHIBITION IN A PHASE 0 TRIAL OF RECURRENT HIGH-GRADE GLIOMA. Neuro-Oncology 2023, 25: v78-v79. PMCID: PMC10639373, DOI: 10.1093/neuonc/noad179.0305.Peer-Reviewed Original ResearchHigh-grade gliomasRecurrent high-grade gliomaPhase 0 trialsStandard therapyPharmacodynamic effectsSurgical specimensMTOR inhibitionAdult high-grade gliomasCDKN2A/B deletionsDose-escalation cohortsIDH wild-type tumorsPharmacokinetics/pharmacodynamicsUnbound drug concentrationsGlioma cell linesRibociclib treatmentCell cycle inhibitionPIK3CA mutationsPreoperative MRIGlioma patientsRibociclibEverolimus concentrationsUnbound concentrationsPatientsSurgical tissuesB deletionBSBM-18 SINGLE-CELL PROFILING TUMOR-INFILTRATING IMMUNE CELLS REVEALS CXCL13+ FOLLICULAR HELPER-LIKE CD4+ T CELLS IN HUMAN BRAIN TUMORS
Lu B, Lucca L, DiStasio M, Liu Y, Pham G, Buitrago-Pocasangre N, Arnal-Estape A, Moliterno J, Chiang V, Omuro A, Hafler D. BSBM-18 SINGLE-CELL PROFILING TUMOR-INFILTRATING IMMUNE CELLS REVEALS CXCL13+ FOLLICULAR HELPER-LIKE CD4+ T CELLS IN HUMAN BRAIN TUMORS. Neuro-Oncology Advances 2023, 5: iii4-iii4. PMCID: PMC10402449, DOI: 10.1093/noajnl/vdad070.014.Peer-Reviewed Original ResearchT cell populationsT cell functionT cellsHigh-grade gliomasBrain metastasesHuman brain tumorsImmune cellsBrain tumorsNon-small cell lung cancer brain metastasesB cellsAnti-PD-1 therapy responseCell lung cancer brain metastasesLung cancer brain metastasesProductive antitumor immune responsesFollicular helper T cellsT-cell receptor sequencingTumor-infiltrating T cellsAntitumor T-cell functionCancer brain metastasesCo-inhibitory receptorsAntitumor immune responseCell receptor sequencingLonger overall survivalCell functionTertiary lymphoid structuresThe genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.
Lustberg M, Kaneva K, Teslow E, Mauer E, Federman N, Eisfeld A. The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing. Journal Of Clinical Oncology 2023, 41: e15091-e15091. DOI: 10.1200/jco.2023.41.16_suppl.e15091.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor mutational burdenCancer patientsAYA patientsMicrosatellite instabilityBreast cancerNext-generation sequencingYoung adult cancer patientsYoung adult malignancyColorectal cancer patientsAdult cancer patientsHER2- breast cancerOlder adult patientsAYA cancer patientsSoft tissue sarcomasCentral nervous systemHigh-grade gliomasLow-grade gliomasPathogenic single nucleotide variantsAYA cancerSingle nucleotide variantsAdult patientsGastrointestinal malignanciesNTRK fusionsAML subgroups
2022
NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials and clinics
Abayazeed A, Abbassy A, Müeller M, Hill M, Qayati M, Mohamed S, Mekhaimar M, Raymond C, Dubey P, Nael K, Rohatgi S, Kapare V, Kulkarni A, Shiang T, Kumar A, Andratschke N, Willmann J, Brawanski A, De Jesus R, Tuna I, Fung S, Landolfi J, Ellingson B, Reyes M. NS-HGlio: A generalizable and repeatable HGG segmentation and volumetric measurement AI algorithm for the longitudinal MRI assessment to inform RANO in trials and clinics. Neuro-Oncology Advances 2022, 5: vdac184. PMID: 36685009, PMCID: PMC9850874, DOI: 10.1093/noajnl/vdac184.Peer-Reviewed Original ResearchHigh-grade gliomasNeuro-Oncology criteriaResidual tumor volumeTreatment response monitoringIntraclass correlation coefficientMRI assessmentTreatment responseTumor volumeResponse assessmentRadiation planningTumor tissueInternal validationResponse monitoringGBM datasetsMRIExternal validationVolumetric measurementsEDDice similarity coefficientUse of longitudinal functional MRI to demonstrate translocation of language function in patients with brain tumors.
Quinones A, Jenabi M, Pasquini L, Peck K, Moss N, Brennan C, Tabar V, Holodny A. Use of longitudinal functional MRI to demonstrate translocation of language function in patients with brain tumors. Journal Of Neurosurgery 2022, 139: 29-37. PMID: 36433876, DOI: 10.3171/2022.10.jns221212.Peer-Reviewed Original ResearchConceptsLongitudinal functional MRILanguage functionInvolvement of BAFunctional MRILaterality indexBroca's areaLow-grade gliomasIncidence of aphasiaHigh-grade gliomasFunctional MRI studiesEloquent language areasReorganized groupCortical reorganizationConstant groupLanguage lateralizationBrain tumorsAuthors investigated changesLanguage areasFMRI examinationDecreased LIAssociated with tumor involvementEloquent areasLeft dominanceRight dominanceAphasiaSingle cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma
Coy S, Wang S, Stopka S, Lin J, Yapp C, Ritch C, Salhi L, Baker G, Rashid R, Baquer G, Regan M, Khadka P, Cole K, Hwang J, Wen P, Bandopadhayay P, Santi M, De Raedt T, Ligon K, Agar N, Sorger P, Touat M, Santagata S. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Nature Communications 2022, 13: 4814. PMID: 35973991, PMCID: PMC9381513, DOI: 10.1038/s41467-022-32430-w.Peer-Reviewed Original ResearchConceptsPediatric high-grade gliomasHigh-grade gliomasDiffuse midline gliomaH3K27M-mutant diffuse midline gliomaAstrocyte-like differentiationPoor outcomeInflammatory microenvironmentClinical significanceMidline gliomaTherapeutic targetingMyeloid cellsPurinergic signalingImmune adaptationEGFR amplificationTumor cellsGliomasExtracellular purinergicPurinergicGlioblastomaCD39CD73Functional stateMicroenvironmentMicrogliaCellsBrain Functional Connectivity in Low- and High-Grade Gliomas: Differences in Network Dynamics Associated with Tumor Grade and Location
Pasquini L, Jenabi M, Yildirim O, Silveira P, Peck K, Holodny A. Brain Functional Connectivity in Low- and High-Grade Gliomas: Differences in Network Dynamics Associated with Tumor Grade and Location. Cancers 2022, 14: 3327. PMID: 35884387, PMCID: PMC9324249, DOI: 10.3390/cancers14143327.Peer-Reviewed Original ResearchTumor gradeHigh-gradeHealthy controlsTumor locationTemporal tumorClinical dataTwo-tailed Student's t-testSubgroup of patientsHigh-grade gliomasMann-Whitney U testStudent's t-testMagnetic resonance imagingInsular tumorsBilateral decreaseFunctional magnetic resonance imagingLow-gradeGlioma patientsTumorClinical deficitsBrain tumorsMann-WhitneyResting-state functional magnetic resonance imagingPatientsResonance imagingAnalyzed whole brainMODL-22. Establishment of a novel system to specifically trace and ablate quiescent/slow cycling cells in high-grade glioma
Antonica F, Santomaso L, Pernici D, Petrucci L, Aiello G, Cutarelli A, Conti L, Romanel A, Miele E, Tebaldi T, Tiberi L. MODL-22. Establishment of a novel system to specifically trace and ablate quiescent/slow cycling cells in high-grade glioma. Neuro-Oncology 2022, 24: i173-i173. DOI: 10.1093/neuonc/noac079.645.Peer-Reviewed Original ResearchSlow-cycling cellsHigh-grade gliomasBrain cancerCancer organoidsTumor infiltrationHigh-grade brain cancerAdult high-grade gliomasTumor cellsHigh-grade glioma patientsCommon malignant brain tumorCycling tumor cellsPediatric high-grade glioma patientsMalignant brain tumorsSlow cycling stem cellsCycling cellsHuman tumor samplesPoor prognosisSurgical removalMalignant featuresTumor relapseGlioma patientsMouse modelBrain tumorsTemozolomide treatmentMalignant cellsMulticenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.
Fanucci K, Pilat M, Shah R, Boerner S, Li J, Durecki D, Drappatz J, Collichio F, Puduvalli V, Lieberman F, Gonzalez J, Giglio P, Bao X, Ivy S, Bindra R, Omuro A, LoRusso P. Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma. Journal Of Clinical Oncology 2022, 40: 2035-2035. DOI: 10.1200/jco.2022.40.16_suppl.2035.Peer-Reviewed Original ResearchProgression-free survivalMedian progression-free survivalStable diseaseDuration of responseOverall response ratePARP inhibitorsOverall survivalStandard therapyOlaparib monotherapyMulticenter phase 2 trialCDKN2A deletionClinical predictive markersGrade 3 lymphopeniaProlonged stable diseasePhase 2 trialGrade 4 tumorsFuture patient stratificationRecent preclinical studiesHigh-grade gliomasNovel drug combinationsContrast-enhancing gliomasEligible ptsEvaluable ptsRecent histologyPrimary endpointSpatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma
Kim A, Choi S, Park J, Kwon M, Chowdhury T, Yu H, Kim S, Kang H, Kim K, Park S, Park C, Shin E. Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma. OncoImmunology 2022, 11: 2026019. PMID: 35036078, PMCID: PMC8757477, DOI: 10.1080/2162402x.2022.2026019.Peer-Reviewed Original ResearchConceptsHigh-grade gliomasTumor immune microenvironmentTumor-associated macrophagesM2 tumor-associated macrophagesT cellsExhausted CD8Immune cellsImmunosuppressive cellsCTLA-4Hypoxic conditionsImmunosuppressive tumor immune microenvironmentProgression-free survivalRegulatory T cellsSurvival of patientsImmunosuppressive profilePD-1Patient survivalImmune microenvironmentImmune heterogeneityHypoxia signatureCD8Different biological featuresPatientsFlow cytometrySurvival
2021
AI and High-Grade Glioma for Diagnosis and Outcome Prediction: Do All Machine Learning Models Perform Equally Well?
Pasquini L, Napolitano A, Lucignani M, Tagliente E, Dellepiane F, Rossi-Espagnet M, Ritrovato M, Vidiri A, Villani V, Ranazzi G, Stoppacciaro A, Romano A, Di Napoli A, Bozzao A. AI and High-Grade Glioma for Diagnosis and Outcome Prediction: Do All Machine Learning Models Perform Equally Well? Frontiers In Oncology 2021, 11: 601425. PMID: 34888226, PMCID: PMC8649764, DOI: 10.3389/fonc.2021.601425.Peer-Reviewed Original ResearchHigh-grade gliomasKi-67 expressionEpidermal growth factor receptor vIIIMagnetic resonance imagingOverall survivalKi-67Pathologic diagnosis of high-grade gliomaRadiomics modelRadiomic featuresDiagnosis of high-grade gliomaO-6-methylguanine-DNA methyltransferaseContrast-enhancing tumorOutcome predictionIsocitrate dehydrogenase mutationAdvanced magnetic resonance imagingConfidence intervalsNon-enhancing tumorTumor histologyMGMT methylationPathological diagnosisAdult patientsClinical dataPromoter methylationResonance imagingTumorPersonalised, image-guided, noninvasive brain stimulation in gliomas: Rationale, challenges and opportunities
Sprugnoli G, Rossi S, Rotenberg A, Pascual-Leone A, El-Fakhri G, Golby A, Santarnecchi E. Personalised, image-guided, noninvasive brain stimulation in gliomas: Rationale, challenges and opportunities. EBioMedicine 2021, 70: 103514. PMID: 34391090, PMCID: PMC8365310, DOI: 10.1016/j.ebiom.2021.103514.Peer-Reviewed Original ResearchConceptsHigh-grade gliomasNeuronal activityBrain tumorsProximity of tumor cellsSlow tumor growthAggressive human cancersMalignant brain tumorsBrain stimulationTumor mitosisHealthy brain tissuePatient survivalMechanism of actionImage-guidedTumor cellsTumor growthSynaptic activityHuman cancersTumorTherapeutic interventionsClinical settingNoninvasive brain stimulationElectrical stimulationWhole-brain levelPatientsBrain tissueTopographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas
Kazarian E, Marks A, Cui J, Darbinyan A, Tong E, Mueller S, Cha S, Aboian MS. Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas. Scientific Reports 2021, 11: 14377. PMID: 34257334, PMCID: PMC8277861, DOI: 10.1038/s41598-021-92943-0.Peer-Reviewed Original ResearchConceptsHigh-grade gliomasDiffuse midline gliomaPediatric diffuse midline gliomasMidline gliomaGene panel testingDriver mutationsPanel testingTumor board reviewK27M mutationPediatric patientsNormal gene expression patternsH3 K27M-mutationImaging featuresPreoperative MRIEndogenous gene expressionCerebral hemispheresGliomas correlatesNormal brainGene expression patternsMutation testingPatientsTopographic distributionGliomasM mutationIDH1 mutationOptimal timing of post-operative enoxaparin after neurosurgery: A single institution experience
Briggs RG, Lin YH, Dadario NB, Young IM, Conner AK, Xu W, Tanglay O, Kim SJ, Fonseka RD, Bonney PA, Chakraborty AR, Nix CE, Flecher LR, Yeung JT, Teo C, Sughrue ME. Optimal timing of post-operative enoxaparin after neurosurgery: A single institution experience. Clinical Neurology And Neurosurgery 2021, 207: 106792. PMID: 34233235, DOI: 10.1016/j.clineuro.2021.106792.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisLower extremity deep vein thrombosisExtremity deep vein thrombosisIntracranial tumor resectionVenous thromboembolismAnticoagulant prophylaxisProphylactic enoxaparinTumor resectionImmediate post-operative periodMultivariate binomial logistic regression analysisNon-anticoagulation groupSingle institution experiencePost-operative periodPossible risk factorsPost-operative brain tumor patientsEvidence-based protocolsBrain tumor patientsLogistic regression analysisHigh-grade gliomasBinomial logistic regression analysisVTE complicationsElective craniotomyMedical comorbiditiesPulmonary embolismAdult patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply